Early Phase 1 N=4 High Frequency SARS for Neurogenic Bladder and Bowel Emptying
Spinal Cord Injury
Primary: Urethral Sphincter Pressure — 50 cmH2O
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=90 Clinical Trial Comparing Two Bladder Instillations for IC/BPS
Interstitial Cystitis · Bladder Pain Syndrome
Primary: Change From Baseline in Treatment Response as Measured by the Total Score on the O'Leary-Sant Questionnaire — -6.7; -5.8 scores on a scale
N/A N=65 Study of Weekly Radiotherapy for Bladder Cancer
Bladder Cancer
Primary: Proportion of Patients Experiencing Severe Acute Non-genitourinary Side Effects Following Radiotherapy. — 4; 2 Participants
Phase 2 N=29 Neoadjuvant ABI-007, Carboplatin and Gemcitabine in Locally Advanced Bladder Cancer
Bladder Cancer
Primary: Percentage of Patients With Complete Pathologic Response After 3 Cycles of Treatment — 27.3 percentage of patients
N/A N=10 A Pilot Study Investigating the Use of a Therapeutic Wand in Addition to Physiotherapy for Bladder Pain Syndrome
Painful Bladder Syndrome
Primary: Change in O'Leary-Sant Interstitial Cystitis Symptom Index Score — -4.25; -6.2; 0; -1.8 units on a scale
Phase 1 N=12 Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG)
Urinary Bladder Neoplasms
Primary: Number of Grades 1-5 Adverse Events — 12; 3; 15; 9 adverse events
N/A N=174 Recovery Support for Bladder Cancer Patients and Caregivers
Bladder Cancer · Patient Engagement · Patient Empowerment
Primary: Quality of Life Patient: The Functional Assessment of Cancer Therapy-Bladder Cancer-Cystectomy — 117.59; 118.70 Quality of Life Score — p=0.772
Phase 2 N=43 Bacillus Calmette-Guerin Followed by Sunitinib for the Treatment of High Risk Non-muscle Invasive Lower Urinary Tract Urothelial Carcinoma
Urinary Tract Urothelial Carcinoma
Primary: Number of Participants With Complete Response at 3 Months — 26 Participants
Phase 2 N=27 Safety Study of Recombinant Human Hyaluronidase (Chemophase) in Combination With Mitomycin in Participants With Superficial Bladder Cancer
Bladder Cancer
Primary: Maximum Tolerated Dose (MTD) of Chemophase in Combination With MMC — 800000 Units
N/A N=11 Brain Targets in Patients With Bladder Emptying Difficulties
Neurogenic Bladder · Multiple Sclerosis · Voiding Dysfunction
Primary: Changes in Brain Activity After Treatment Measured Using Functional MRI — 2.759234; 3.423569; 3.000987; 3.094914 BOLD fMRI T-Value — p=<0.05
Phase 2 N=24 A Study Called ARAMON to Learn to What Extent Does Study Treatment With Darolutamide Affects Testosterone Levels in Men With Prostate Cancer That Had Not Been Treated With Hormonal Therapy Compared to Treatment With Enzalutamide
Biochemically Recurrent Prostate Cancer
Primary: Percent Change in Serum Testosterone — 53.46 percentage (%)
N/A N=12 TracelT Hydrogel in Localizing Bladder Tumors in Patients Undergoing Radiation Therapy for Bladder Cancer
Bladder Carcinoma
Primary: Changes in Interfraction Motion of the Marker Measured by Cone Beam Computed Tomography (CT) and x/y/z Coordinates — 0.62 cm
Phase 2 N=32 Durvalumab Plus Tremelimumab With Concurrent Radiotherapy for Localized Muscle Invasive Bladder Cancer Treated With a Selective Bladder Preservation Approach
Invasive Bladder Cancer
Primary: Proportion of Patients With Pathological Response — 26; 2 Participants
Phase 3 N=406 S0337, Gemcitabine After Surgery in Treating Patients With Newly Diagnosed or Recurrent Bladder Cancer
Bladder Cancer
Primary: Disease Recurrence Rate — 27.86; 40 percentage of patients with recurrence — p=0.01
Phase 2 N=15 Proliposomal Intravesical Paclitaxel for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer
Bladder Cancer Cell Transitional · Non-Muscle Invasive Bladder Cancer · Bladder Cancer
Primary: Part 1: Maximum Tolerated Dose or Maximum Deliverable Dose (MDD) — NA; 360 mg